This summary was created by AI, based on 10 opinions in the last 12 months.
Vertex Pharmaceuticals Inc. (VRTX-Q) has garnered a mixed but generally positive outlook from multiple experts. Many commend the company's advancement in pain management drugs, particularly non-addictive options, which are anticipated to receive FDA approvals in the near future. Despite a past pullback, the stock has experienced a notable rise in 2023, attributed to the successful launch of its pain medicine. However, some experts express caution due to disappointing news regarding a key drug and concerns about the company's financials heading into 2024. Overall, the pipeline and positive developments in cystic fibrosis treatments bolster a generally optimistic long-term perspective on the stock.
Vertex Pharmaceuticals Inc. is a American stock, trading under the symbol VRTX-Q on the NASDAQ (VRTX). It is usually referred to as NASDAQ:VRTX or VRTX-Q
In the last year, 6 stock analysts published opinions about VRTX-Q. 2 analysts recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Vertex Pharmaceuticals Inc..
Vertex Pharmaceuticals Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Vertex Pharmaceuticals Inc..
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
6 stock analysts on Stockchase covered Vertex Pharmaceuticals Inc. In the last year. It is a trending stock that is worth watching.
On 2025-04-02, Vertex Pharmaceuticals Inc. (VRTX-Q) stock closed at a price of $483.49.
A strong performer in this market, not pulling back. Everybody is excited over their pain drug, and other drugs in the pipeline as well.